Post-treatment with Meloxicam Attenuates MPP+-Induced Neurotoxicity via PI3K/Akt-Dependent Maintenance of Mcl-1
Biological and Pharmaceutical Bulletin · 2026
DOI: 10.1248/bpb.b26-00348 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2026. Verfasst von Yasuhiro Matsuura und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Pharmacy & Pharmacology, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan. Hauptthemen laut MEDLINE: Meloxicam, Myeloid Cell Leukemia Sequence 1 Protein, Neuroprotective Agents. Die Arbeit nennt 24 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hospital Pharmacy & Pharmacology, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan.
- Department of Nursing, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan.
- Department of Pharmaceutical Sciences, Hokkaido University of Science, Sapporo 006-8585, Japan.
Zitieren
APA
Matsuura, Y., Manabe, T., Ohkubo, T., Kanda, M., Iwayama, K., Kamiyama, N., Chuma, M., & Tasaki, Y. (2026). Post-treatment with Meloxicam Attenuates MPP+-Induced Neurotoxicity via PI3K/Akt-Dependent Maintenance of Mcl-1. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b26-00348
Vancouver
Matsuura Y, Manabe T, Ohkubo T, Kanda M, Iwayama K, Kamiyama N, et al. Post-treatment with Meloxicam Attenuates MPP+-Induced Neurotoxicity via PI3K/Akt-Dependent Maintenance of Mcl-1. Biological and Pharmaceutical Bulletin. 2026. doi:10.1248/bpb.b26-00348
BibTeX
@article{Matsuura2026,
author = {Matsuura, Yasuhiro and Manabe, Takayuki and Ohkubo, Tomoko and Kanda, Masaya and Iwayama, Kuninori and Kamiyama, Naoya and Chuma, Masayuki and Tasaki, Yoshikazu},
title = {Post-treatment with Meloxicam Attenuates MPP+-Induced Neurotoxicity via PI3K/Akt-Dependent Maintenance of Mcl-1},
journal = {Biological and Pharmaceutical Bulletin},
year = {2026},
doi = {10.1248/bpb.b26-00348}
}
EUVIMED